Suppr超能文献

使用维尔博狂犬病疫苗预防狂犬病:1985 - 2005年二十年临床经验

Preventing rabies with the Verorab vaccine: 1985-2005 Twenty years of clinical experience.

作者信息

Toovey Stephen

机构信息

Burggartenstrasse 32, 4103 Bottmingen, Switzerland.

出版信息

Travel Med Infect Dis. 2007 Nov;5(6):327-48. doi: 10.1016/j.tmaid.2007.07.004. Epub 2007 Sep 17.

Abstract

Purified rabies vaccine cultured on Vero cells (Verorab, sanofi pasteur) is WHO-approved for pre- and post-exposure prophylaxis by intradermal and intramuscular routes. During 20 years of use, over 40 million doses of Verorab have been administered in more than 100 countries. No serious adverse event due to Verorab has been reported in clinical trials involving 3937 persons, and Verorab is better tolerated than human diploid cell vaccine (HDCV). Pre-exposure prophylaxis is confirmed immunogenic in 1437 subjects by all routes, with prompt responses following boosting; Verorab boosts effectively subjects pre-immunized with HDCV. Unlike HDCV, Verorab is not associated with post-boosting serum sickness. In the absence of data in immunodeficient/HIV-positive individuals, pre-exposure immunization is urged as early as possible. Essen, Zagreb, Thai Red Cross Intradermal (TRC-ID) and other post-exposure intramuscular and intradermal regimens are documented. Two thousand one hundred and eighty-three subjects received post-exposure prophylaxis, including 874 high risk, severe or confirmed rabid attacks. Co-administration of rabies immune globulin (RIG) does not affect neutralizing antibody levels when Essen or TRC-ID regimens are employed; levels are lower with the Zagreb regimen. Verorab has been administered safely and effectively post-exposure to 251 pregnant women, without any increase in congenital malformations or spontaneous abortions. From a pediatric perspective, safety and efficacy have been demonstrated in 759 children (0-15 years). Intradermal post-exposure Verorab is an effective and inexpensive option for developing countries. Inadvertent subcutaneous administration does not reduce immunogenicity. WHO already strongly recommends the replacement of nerve tissue vaccines with modern vaccines. Extensive clinical experience supports the use of Verorab for intramuscular and intradermal pre- and post-exposure prophylaxis, including in special situations.

摘要

Vero细胞培养的纯化狂犬病疫苗(Vero狂犬病疫苗,赛诺菲巴斯德公司生产)经世界卫生组织批准,可通过皮内和肌肉注射途径进行暴露前和暴露后预防。在20年的使用过程中,超过4000万剂Vero狂犬病疫苗已在100多个国家使用。在涉及3937人的临床试验中,未报告因Vero狂犬病疫苗导致的严重不良事件,并且Vero狂犬病疫苗的耐受性优于人二倍体细胞疫苗(HDCV)。暴露前预防通过所有途径在1437名受试者中证实具有免疫原性,加强免疫后反应迅速;Vero狂犬病疫苗能有效增强预先接种HDCV的受试者的免疫力。与HDCV不同,Vero狂犬病疫苗与加强免疫后血清病无关。由于缺乏免疫缺陷/艾滋病毒阳性个体的数据,敦促尽早进行暴露前免疫。埃森、萨格勒布、泰国红十字会皮内注射(TRC-ID)以及其他暴露后肌肉注射和皮内注射方案均有记录。2183名受试者接受了暴露后预防,其中包括874例高风险、严重或确诊的狂犬病发作。采用埃森或TRC-ID方案时,狂犬病免疫球蛋白(RIG)的联合使用不影响中和抗体水平;萨格勒布方案的中和抗体水平较低。Vero狂犬病疫苗已在251名孕妇暴露后安全有效地使用,未出现先天性畸形或自然流产增加的情况。从儿科角度来看,已在759名儿童(0至15岁)中证明了其安全性和有效性。皮内注射Vero狂犬病疫苗是发展中国家一种有效且廉价的选择。意外皮下注射不会降低免疫原性。世界卫生组织已强烈建议用现代疫苗替代神经组织疫苗。广泛的临床经验支持使用Vero狂犬病疫苗进行肌肉注射和皮内注射的暴露前和暴露后预防,包括在特殊情况下。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验